-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Immunome, Raises Price Target to $35

Benzinga·12/16/2025 13:48:18
语音播报
Guggenheim analyst Michael Schmidt maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $25 to $35.